Anastrozole had a better risk-benefit profile than tamoxifen as adjuvant treatment for breast cancer in postmenpausal women

Hillner, Bruce E.
January 2007
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p4
Academic Journal
The article cites a study on the use of anastrozole and tamoxifen as adjuvant treatment by postmenopausal women in the early stages of breast cancer. The study was conducted by researcher A. Buzdar and colleagues, and was published in an issue of the journal "The Lancet Oncology." The study reported that women taking anastrozole were less likely to have treatment-related adverse events. The study also showed that the women taking tamoxifen were more prone to side effects.


Related Articles

  • CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Sirachainan, Ekaphop; Jaruhathai, Sureerat; Trachu, Narumol; Panvichian, Ravat; Sirisinha, Thitiya; Ativitavas, Touch; Ratanatharathorn, Vorachai; Chamnanphon, Montri; Sukasem, Chonlaphat // Pharmacogenomics & Personalized Medicine;2012 Part 2, Vol. 5, p149 

    Aim: We evaluated single nucleotide polymorphisms (SNPs) of CYP2D6 to identify those that influence the efficiency of tamoxifen in adjuvant treatment of breast cancer through a matched case-control study. Methods: Peripheral blood DNA was collected from 20 patients with disease recurrence during...

  • The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Hozumi, Y.; Suemasu, K.; Takei, H.; Aihara, T.; Takehara, M.; Saito, T.; Ohsumi, S.; Masuda, N.; Ohashi, Y. // Annals of Oncology;Aug2011, Vol. 22 Issue 8, p1777 

    Background: In this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated with exemestane, anastrozole, or tamoxifen for postoperative adjuvant...

  • PI-29. Ntukidem, N. I.; Blanche, P.; Li, L.; Krauss, R. M.; Skaar, T. C.; Desta, Z.; Storniolo, A. M.; Stearns, V.; Hayes, D. F.; Flockhart, D. A. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP15 

    Background: Small dense LDL particles are associated with increased atherogenicity. We examined the effect of tamoxifen treatment on LDL subfraction particle size.Methods: 49 breast cancer patients were prospectively followed on adjuvant tamoxifen treatment. LDL peak particle size measurements...

  • Letrozole. Keating, Gillian M. // Drugs;2009, Vol. 69 Issue 12, p1681 

    Letrozole (Femara®) is a third-generation, nonsteroidal aromatase inhibitor. Adjuvant therapy with letrozole is more effective than tamoxifen in postmenopausal women with hormone-responsive early breast cancer, and extended adjuvant therapy with letrozole after the completion of adjuvant...

  • Tamoxifen use and gallstone formation in postmenopausal breast cancer patients in south Indian population. Mohamed, A. P. A.; Kadambari, D.; Bhuvaneswari, V. // Indian Journal of Cancer;Apr-Jun2009, Vol. 46 Issue 2, p151 

    BACKGROUND: Tamoxifen is being used in patients with estrogen receptor positive breast cancer as an adjuvant or palliative hormonal therapy. western studies have found a 30% incidence of gallstones in patients who are taking Tamoxifen and they have proved a significant association between the...

  • Letrozole: A Review of its Use in the Treatment of Postmenopausal Women with Hormone-Responsive Early Breast Cancer. Keating, Gillian M. // Drugs;Aug2009, Vol. 69 Issue 12, p1681 

    Summary: Letrozole (Femara®) is a third-generation, nonsteroidal aromatase inhibitor. Adjuvant therapy with letrozole is more effective than tamoxifen in post-menopausal women with hormone-responsive early breast cancer, and extended adjuvant therapy with letrozole after the completion of...

  • Epoetin Alfa: To Give or Not to Give. Dang, Chau; Hudis, Clifford; Norton, Larry // JNCI: Journal of the National Cancer Institute;7/17/2013, Vol. 105 Issue 14, p1001 

    The author presents a commentary on a paper which reported that an erythropoiesis stimulation agent (ESA) can safely treat chemotherapy-induced anemia in patients with breast cancer receiving adjuvant therapy. A second randomization among patients in the intense dose-dense (IDD) arm to receive...

  • Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality. Munoz, Diego; Near, Aimee M.; van Ravesteyn, NicolienT.; Lee, Sandra J.; Schechter, Clyde B.; Alagoz, Oguzhan; Berry, Donald A.; Burnside, Elizabeth S.; Yaojen Chang; Chisholm, Gary; de Koning, Harry J.; Ergun, Mehmet Ali; Heijnsdijk, Eveline A. M.; Hui Huang; Stout, Natasha K.; Sprague, Brian L.; Trentham-Dietz, Amy; Mandelblatt, Jeanne S.; Plevritis, Sylvia K. // JNCI: Journal of the National Cancer Institute;Nov2014, Vol. 106 Issue 11, p1 

    Background Molecular characterization of breast cancer allows subtype-directed interventions. Estrogen receptor (ER) is the longest-established molecular marker. Methods We used six established population models with ER-specific input parameters on age-specific incidence, disease natural...

  • Extended tamoxifen improved survival in ER-positive breast cancer.  // Hem/Onc Today;1/10/2013, Vol. 14 Issue 1, p1 

    The article presents the results of the international Adjuvant Tamoxifen--Longer Against Shorter (ATLAS) trials, which found that women with breast cancer who underwent adjuvant tamoxifen treatment for 10 years survived longer and had fewer recurrences than those who underwent 5-year treatments.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics